These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 20602557)

  • 21. Predicting the long-term effects of cardiac resynchronization therapy on mortality from baseline variables and the early response a report from the CARE-HF (Cardiac Resynchronization in Heart Failure) Trial.
    Cleland J; Freemantle N; Ghio S; Fruhwald F; Shankar A; Marijanowski M; Verboven Y; Tavazzi L
    J Am Coll Cardiol; 2008 Aug; 52(6):438-45. PubMed ID: 18672164
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Upgrading to resynchronization therapy after chronic right ventricular pacing improves left ventricular remodelling.
    Fröhlich G; Steffel J; Hürlimann D; Enseleit F; Lüscher TF; Ruschitzka F; Abraham WT; Holzmeister J
    Eur Heart J; 2010 Jun; 31(12):1477-85. PubMed ID: 20233792
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiac resynchronization therapy in heart failure patients: an update.
    Jeevanantham V; Daubert JP; Zareba W
    Cardiol J; 2009; 16(3):197-209. PubMed ID: 19437393
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic cardiac resynchronization therapy reverses cardiac remodelling and improves invasive haemodynamics of patients with severe heart failure on optimal medical treatment.
    Inage T; Yoshida T; Hiraki T; Ohe M; Takeuchi T; Nagamoto Y; Fukuda Y; Gondo T; Imaizumi T
    Europace; 2008 Mar; 10(3):379-83. PubMed ID: 18227354
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CRT plus ICD in congestive heart failure. Use of cardiac resynchronization therapy and an implantable cardioverter-defibrillator in heart failure patients with abnormal left ventricular dysfunction.
    Aronow WS
    Geriatrics; 2005 Feb; 60(2):24, 26-8. PubMed ID: 15742919
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Very long term follow-up of cardiac resynchronization therapy: clinical outcome and predictors of mortality.
    Kronborg MB; Mortensen PT; Kirkfeldt RE; Nielsen JC
    Eur J Heart Fail; 2008 Aug; 10(8):796-801. PubMed ID: 18619900
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Usefulness of QRS duration to predict response to cardiac resynchronization therapy in patients with end-stage heart failure.
    Mollema SA; Bleeker GB; van der Wall EE; Schalij MJ; Bax JJ
    Am J Cardiol; 2007 Dec; 100(11):1665-70. PubMed ID: 18036366
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metaanalysis on effects of cardiac resynchronization therapy in heart failure patients with narrow QRS complex.
    Jeevanantham V; Zareba W; Navaneethan S; Fitzgerald D; Yu CM; Achilli A; Bax J; Daubert J
    Cardiol J; 2008; 15(3):230-6. PubMed ID: 18651415
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epicardial left ventricular lead placement for cardiac resynchronization therapy: optimal pace site selection with pressure-volume loops.
    Dekker AL; Phelps B; Dijkman B; van der Nagel T; van der Veen FH; Geskes GG; Maessen JG
    J Thorac Cardiovasc Surg; 2004 Jun; 127(6):1641-7. PubMed ID: 15173718
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the effects of cardiac resynchronization therapy in patients with class II versus class III and IV heart failure (from the InSync/InSync ICD Italian Registry).
    Landolina M; Lunati M; Gasparini M; Santini M; Padeletti L; Achilli A; Bianchi S; Laurenzi F; Curnis A; Vincenti A; Valsecchi S; Denaro A;
    Am J Cardiol; 2007 Sep; 100(6):1007-12. PubMed ID: 17826388
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Cardiac resynchronization therapy by biventricular pacing. How many patients with left ventricular dysfunction are eligible?].
    Yang A; Wolpert C; Schimpf R; Schulz T; Krause U; Jung W; Herwig S; Jeong KM; Omran H; Lewalter T; Lüderitz B
    Dtsch Med Wochenschr; 2002 Oct; 127(43):2259-63. PubMed ID: 12397540
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial: rationale, design, results, clinical implications and lessons for future trials.
    Wilkoff BL;
    Card Electrophysiol Rev; 2003 Dec; 7(4):468-72. PubMed ID: 15071277
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure.
    Abraham WT; Young JB; León AR; Adler S; Bank AJ; Hall SA; Lieberman R; Liem LB; O'Connell JB; Schroeder JS; Wheelan KR;
    Circulation; 2004 Nov; 110(18):2864-8. PubMed ID: 15505095
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Longitudinal strain delay index by speckle tracking imaging: a new marker of response to cardiac resynchronization therapy.
    Lim P; Buakhamsri A; Popovic ZB; Greenberg NL; Patel D; Thomas JD; Grimm RA
    Circulation; 2008 Sep; 118(11):1130-7. PubMed ID: 18725491
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biventricular pacing and cardiac resynchronization therapy: a fresh approach to heart failure and intraventricular conduction delay.
    Mardell AP
    Can J Cardiovasc Nurs; 2004; 14(1):29-38. PubMed ID: 15022530
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Progression of heart failure in right univentricular pacing compared to biventricular pacing.
    Ritter O; Koller ML; Fey B; Seidel B; Krein A; Langenfeld H; Bauer WR
    Int J Cardiol; 2006 Jun; 110(3):359-65. PubMed ID: 16297471
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heart rate variability in patients suffering from structural heart disease and decreased AV-nodal conduction capacity. Insights into the formation of heart rate variability.
    Schwab JO; Eichner G; Schmitt H; Schrickel J; Yang A; Balta O; Lüderitz B; Lewalter T
    Z Kardiol; 2004 Mar; 93(3):229-33. PubMed ID: 15024591
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Electrocardiographic remodeling during cardiac resynchronization therapy.
    Boriani G; Biffi M; Martignani C; Ziacchi M; Saporito D; Grigioni F; Domenichini G; Valzania C; Diemberger I; Bertini M; Specchia S; Branzi A
    Int J Cardiol; 2006 Apr; 108(2):165-70. PubMed ID: 15923048
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized comparison of triple-site versus dual-site ventricular stimulation in patients with congestive heart failure.
    Leclercq C; Gadler F; Kranig W; Ellery S; Gras D; Lazarus A; Clémenty J; Boulogne E; Daubert JC;
    J Am Coll Cardiol; 2008 Apr; 51(15):1455-62. PubMed ID: 18402900
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of cardiac resynchronization therapy on the mechanisms underlying functional mitral regurgitation in congestive heart failure.
    Porciani MC; Macioce R; Demarchi G; Chiostri M; Musilli N; Cappelli F; Lilli A; Ricciardi G; Padeletti L
    Eur J Echocardiogr; 2006 Jan; 7(1):31-9. PubMed ID: 16378918
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.